Biocryst Pharmaceuticals (BCRX) Enterprise Value (2010 - 2026)

Biocryst Pharmaceuticals has reported Enterprise Value for 17 years, with the latest figure at -$238.4 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 25.35% year-over-year to -$238.4 million; the trailing twelve-month figure through Mar 2026 stood at -$238.4 million (down 25.35% YoY), and the FY2025 full-year result was -$274.7 million, up 14.37% from the prior year.
• Enterprise Value for Q1 2026 stood at -$238.4 million, up from -$274.7 million in the prior quarter.
• The five-year high for Enterprise Value was -$51.3 million in Q1 2022, with the low at -$426.9 million in Q3 2022.
• Historically, Enterprise Value has averaged -$271.3 million across 5 years, with a median of -$274.7 million in 2025.
• The largest YoY upside for Enterprise Value was 76.16% in 2022 against a maximum downside of 1074.45% in 2022.
• Biocryst Pharmaceuticals' Enterprise Value stood at -$121.0 million in 2022, then tumbled by 221.44% to -$389.0 million in 2023, then gained by 17.52% to -$320.8 million in 2024, then grew by 14.37% to -$274.7 million in 2025, then rose by 13.23% to -$238.4 million in 2026.
• The last three Enterprise Value figures came in at -$238.4 million (Q1 2026), -$274.7 million (Q4 2025), and -$212.9 million (Q3 2025), per Business Quant data.